|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
McGill University Health Center |
| Information provided by: | McGill University Health Center |
| ClinicalTrials.gov Identifier: | NCT00627718 |
Purpose
Age Related Macular Degeneration (ARMD) is the most common cause of irreversible blindness in people of age 50 or older in the western populations. ARMD has two forms, the wet and the dry forms. The wet form is more serious and can lead to irreversible loss of vision. In the wet form of ARMD, new blood vessels grow under the retina. These blood vessels leak blood and fluid and cause the retina and the macula to swell. So the thickness of the macula increases.
One of the key factors in the treatment of wet ARMD is early diagnosis and treatment to prevent complete visual loss. In this research, we are going to use a technique, called the Heidelberg retinal tomograph (HRT) to measure and compare the thickness of the macula in healthy controls and in patients suspected of having ARMD. HRT is a non-invasive imaging system that uses laser to measure the thickness of the macula. This allows us to come up with a quite simple and easy-to-use technique that helps us to diagnose wet ARMD early and treat it before visual acuity is completely lost.
| Condition | Intervention |
|
Age-Related Macular Degeneration |
Device: HRT screening for macula edema |
| Genetics Home Reference related topics: | X-linked juvenile retinoschisis |
| MedlinePlus related topics: | Edema Macular Degeneration |
| Study Type: | Interventional |
| Study Design: | Diagnostic, Single Blind (Outcomes Assessor), Single Group Assignment |
| Official Title: | Assessment of Macular Edema Using HRT Technique |
| Estimated Enrollment: | 50 |
| Study Start Date: | April 2008 |
| Estimated Study Completion Date: | July 2009 |
| Estimated Primary Completion Date: | April 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|
A
All patients with possible neovascular ARMD are assessed with HRT to determined the positive predictive value of the test
|
Device: HRT screening for macula edema
HRT screening for macula edema at time of initial diagnosis of macular degeneration
|
![]() |
Show Detailed Description |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Canada, Quebec | |||||
| MUHC | Not yet recruiting | ||||
| Montreal, Quebec, Canada, H3A 1A1 | |||||
| Contact: Mila Oh, MDCM, FRCSC (514) 843-1646 milaoh@videotron.ca | |||||
| Principal Investigator: Mila Oh, MDCM, FRCSC | |||||
| McGill University Health Center |
| Principal Investigator: | Mila Oh, MD | McGill University Health Center |
More Information
| Responsible Party: | MUHC ( Mila Oh, MD ) |
| Study ID Numbers: | BMB 06-029 |
| First Received: | February 22, 2008 |
| Last Updated: | February 29, 2008 |
| ClinicalTrials.gov Identifier: | NCT00627718 |
| Health Authority: | Canada: Ethics Review Committee |
|
|
|